The Exhilirating Movement From Treatment to Cures for Autoimmune Diseases

For several decades, the standard approach to autoimmune diseases has been suppression of the immune system, a treatment with potential serious side effects and, with the common use of injectable monoclonal antibodies, variable efficacy, at very high cost. For example, Humira (adalimumab), an antibody vs tumor necrosis factor used as treatment for many autoimmune diseases, has a list price of over $7,000 a month and was for a decade until 2022 the leading drug by sales worldwide (peak $22 billio...